Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Patent
1993-07-30
1998-04-28
Smith, Lynette F.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
4242791, 4242801, 530350, A61K 3900, A61K 4500, A61K 4505, C07K 100
Patent
active
057441448
ABSTRACT:
The present invention relates to novel synthetic muc-1 peptides and muc-1 analogs comprising at least two 20-amino acid tandem repeats of muc-1, wherein said synthetic muc-1 peptide is capable of attaining native conformation in the absence of glycosylation. The invention also relates methods of producing the peptides. The invention further relates to uses of the peptides, such as for vaccines and diagnostic testing.
REFERENCES:
Gendler, et al, 1988, "A highly immunogenic region of . . . " J. Biol. Chem. 263(26):12820-12823.
Jerome, et al, 1991, "Cytotoxic T-lymphocytes derived from . . . " Cancer Research 51:2908-2916.
Bara, et al, 1993, "A fucose residue can mask the muc-1 . . . " Int. J. Cancer 54 ;607-613.
Hareuveni et al., "Vaccination against tumor cells expressing breast cancer epithelial tumor antigen", Proc. Natl. Acad. Sci. USA, vol. 87, pp. 9498-9502, Dec. 1990, Medical Sciences.
Acres et al., "Vaccinia Virus MUC1 . . . Antigen", Journal of Immunotherapy, 14:136-143, 1993.
Ding et al., "Immunogenicity of synthetic peptides . . . MUC1 gene", Cancer Immunol Immunother (1993), 36: 9-17.
S. J. Gendler et al., "Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium", Proc. Natl. Acad. Sci. USA, vol. 84, pp. 6060-6064, Sep. 1987, Biochemistry.
Nishimori et al., "Influence of Acceptor Substrate Primary Amino Acid . . . N-Acetylgalactosaminyltransferase", The Journal Of Biological Chemistry, The American Society for Biochemistry and Molecular Biology, Inc., vol. 269, No. 23, Issue of Jun. 10, pp. 16123-16130, 1994.
Abstract--"Mucin Based Immunity and Immunotherapy of Cancer", by O.J. Finn, Dept. of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.
J. Darrell Fontenot, et al., Biophysical Characterization of One-, Two-, and Three-Tandem Repeats of Human Mucin (muc-1) Protein Core.sup.1, Cancer Research 53, 5386-5394, Nov. 15, 1993.
J. D. Fontenot, et al., Synthesis of Large Multideterminant Peptide Immunogens Using A Poly-Proline .beta.-Turn Helix Motiff, Peptide Research, 330-336, vol. 6, No. (1993).
Yasuo Kotera, et al., Humoral Immunity against a Tandem Repeat Epitope of Human Mucin MUC-1 in Sera from Breast, Pancreatic, and Colon Cancer Patients.sup.1, Advances in Brief, Cancer Research 54, 2856-2860, Jun. 1, 1994.
Olivera J. Finn, Antigen-specific, MHC-unrestricted T cells, Biotherapy 4: 239-249, 1992, Dept. of Molecular Genetics and Biochemistry, University of Pittsburg School of Medicine, Pittsburgh, PA 15261, USA.
Carol Clayberger et al., Peptides Corresponding to the CD8 and CD4 Binding Domains of HLA Molecules Block T Lymphocyte Immune Responses In Vitro.sup.1, pp. 946-951.
Alessandro Sette et al., Peptide Binding To The Most Frequent HLA-A Class I Alleles Measured By Quantitative Molecular Binding Assays, pp. 813-822.
Niklas Ahlborg et al., "B- and T-cell responses in congenic mice to repeat sequences of the malaria antigen Pf332: effects of the number of repeats", Immunology Letters, 40 (1994) 147-155.
Michael N. Starnbach et al., Cells Infected with Yersinia Present an Epitope to Class I MHC-Restricted CTL.sup.1, The Journal of Immunology, pp. 1603-1612.
Thorsten Vogel et al., The Majority of Neutralizing Abs in HIV-1-Infected Patients Recognize Linear V3 Loop Sequences, (1994) The Journal of Immunology, pp. 1895-1904.
Ichiro Yoshino et al., "HER2
eu-derived Peptides Are Shared Antigens among Human Non-Small Cell Lung Cancer and Ovarian Cancer", Cancer Research 54 3387-3390, Jul. 1, 1994.
Jean-Pierre Cabaniols et al., "Dose-dependent T cell tolerance to an immunodominant self peptide", Eur. J. Immunol. 1994 24: 1743-1749.
Gillies Benichou et al., "Limited T Cell Response to Donor MHC Peptides During Allograft Rejection", The Journal of Immunology, pp. 938-945.
Finn Olivera J.
Fontenot J. Darrell
Montelaro Ronald C.
Smith Lynette F.
University Of Pittsburgh University Patent Committee Policy And
LandOfFree
Synthetic multiple tandem repeat mucin and mucin-like peptides, does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic multiple tandem repeat mucin and mucin-like peptides, , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic multiple tandem repeat mucin and mucin-like peptides, will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1529929